Literature DB >> 25443347

Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases.

Francesco Negro1.   

Abstract

The hepatitis C virus (HCV) is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma worldwide. A significant portion of the morbidity and mortality associated with HCV is a consequence of numerous HCV-associated comorbidities. Type 2 diabetes and atherosclerosis, two known complications of the metabolic syndrome, are noteworthy, because HCV has been suggested to play a role in their pathogenesis. In addition, HCV also causes steatosis, which may increase the risk of cardiovascular events. This review summarizes the evidence supporting the association between HCV and steatosis, insulin resistance/type 2 diabetes and cardiovascular morbidity and mortality. Their diagnostic, prognostic and management aspects are discussed.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Coronary artery disease; Diabetes; Hepatitis C virus; Insulin resistance; Steatosis; Stroke

Mesh:

Year:  2014        PMID: 25443347     DOI: 10.1016/j.jhep.2014.08.003

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  59 in total

1.  Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.

Authors:  Ayumu Yoshikawa; Katsumi Terashita; Kenichi Morikawa; Soichiro Matsuda; Takahiro Yamamura; Koichiro Sarashina; Shintaro Nakano; Yoshimitsu Kobayashi; Susumu Sogabe; Kazuhiro Takahashi; Shin Haba; Hisashi Oda; Tatsuro Takahashi; Takuto Miyagishima; Naoya Sakamoto
Journal:  Clin J Gastroenterol       Date:  2017-04-26

2.  Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.

Authors:  Thomas Ward; Jason Gordon; Beverley Jones; Hayley Bennett; Samantha Webster; Anupama Kalsekar; Yong Yuan; Michael Brenner; Phil McEwan
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

3.  No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.

Authors:  Chloe S Chaudhury; Julia Sheehan; Cheryl Chairez; Elizabeth Akoth; Chloe Gross; Rachel Silk; Sarah Kattakuzhy; Elana Rosenthal; Shyam Kottilil; Henry Masur; Colleen Hadigan
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

4.  Extracellular Interactions between Hepatitis C Virus and Secreted Apolipoprotein E.

Authors:  Zhihua Li; Yadong Li; Yanwei Bi; Hui Zhang; Yufeng Yao; Qihan Li; Wei Cun; Shaozhong Dong
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.

Authors:  Silvia Fabiani; Poupak Fallahi; Silvia Martina Ferrari; Mario Miccoli; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

Review 7.  Metabolic reprogramming: a hallmark of viral oncogenesis.

Authors:  P Lévy; B Bartosch
Journal:  Oncogene       Date:  2015-12-21       Impact factor: 9.867

8.  Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study.

Authors:  Kenneth A Lichtenstein; Rachel L D Hart; Kathleen C Wood; Samuel Bozzette; Kate Buchacz; John T Brooks
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

Review 9.  Assessing cardiovascular risk in hepatitis C: An unmet need.

Authors:  Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-09-08

Review 10.  Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.

Authors:  Yan Wang; Jin-Lin Hou
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.